Urogen Pharma (URGN) Reports Q1 Loss, Misses Revenue Estimates

02:15pm, Tuesday, 10'th May 2022 Zacks Investment Research
Urogen Pharma (URGN) delivered earnings and revenue surprises of 8.09% and 13.16%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Pfizer Acquires Biohaven For $11B Pfizer Inc (NYSE: PFE) will acquire Biohaven Pharmaceutical Hold

Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates

10:15pm, Monday, 09'th May 2022 Zacks Investment Research
Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of -19.40% and 6.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stoc

Prothena (PRTA) Reports Q1 Loss, Tops Revenue Estimates

10:35pm, Thursday, 05'th May 2022 Zacks Investment Research
Prothena (PRTA) delivered earnings and revenue surprises of 8.24% and 401.30%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Upgrades BTIG upgraded the previous rating for Acutus Medical Inc (NASDAQ:AFIB) from Neutral to Buy. In the fourth quarter, Acutus Medical showed an EPS of $1.00, compared to $0.89 from the year-ago
UroGen Pharma Ltd.'s (URGN) CEO Liz Barrett on Q4 2021 Results - Earnings Call Transcript

Urogen Pharma (URGN) Reports Q4 Loss, Tops Revenue Estimates

01:15pm, Monday, 21'st Mar 2022 Zacks Investment Research
Urogen Pharma (URGN) delivered earnings and revenue surprises of -7.63% and 0.15%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Urogen Pharma (URGN) delivered earnings and revenue surprises of -7.63% and 0.15%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Scheduled For March 10, 2022

09:33am, Thursday, 10'th Mar 2022 Benzinga
Companies Reporting Before The Bell • Despegar.com (NYSE: DESP ) is expected to report quarterly loss at $0.08 per share on revenue of $110.93 million. • ProShares UltraShort Russell2000 (NYSE: TWM ) is expected to report earnings for its fourth quarter. • Vivid Seats (NASDAQ: SEAT ) is projected to report quarterly loss at $0.07 per share on revenue of $139.54 million. • LumiraDx (NASDAQ: LMDX ) is expected to report quarterly loss at $0.09 per share on revenue of $69.60 million. • Life Time Group Hldgs (NYSE: LTH ) is expected to report quarterly loss at $0.41 per share on revenue of $356.92 million. • ATRenew (NYSE: RERE ) is likely to report quarterly loss at $0.03 per share on revenue of $368.91 million. • FuelCell Energy (NASDAQ: FCEL ) is estimated to report quarterly loss at $0.05 per share on revenue of $26.73 million. • Zealand Pharma (NASDAQ: ZEAL ) is expected to report quarterly loss at $0.93 per share on revenue of $11.98 million. • Yatsen Holding (NYSE: YSG ) is projected to report quarterly loss at $0.
Conference Call and Webcast Scheduled for Thursday, March 10, 2022 , at 10:00 AM ET PRINCETON, N.J. --(BUSINESS WIRE)--Mar. 4, 2022-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers,
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod

ADC Therapeutics SA (ADCT) Reports Q4 Loss, Tops Revenue Estimates

01:25pm, Thursday, 03'rd Mar 2022 Zacks Investment Research
ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of 55.17% and 3.70%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Tops Revenue Estimates

01:15pm, Tuesday, 01'st Mar 2022 Zacks Investment Research
Rhythm Pharmaceuticals, Inc. (RYTM) delivered earnings and revenue surprises of 15% and 6.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the s
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq:URGN), a biotech company dedicated to developing and commercializing innovative solutions to treat urothelial and specialty cancers, today announced that it will participate in a panel discussion at the upcoming virtual Cowen 42nd Annual Healthcare Conference on March 8, 2022 at 10:30am Eastern Time. A live webcast of the panel will be available on the Investors & Media section of UroGen’s website at www.urogen.com. A replay of th

Curis (CRIS) Reports Q4 Loss, Tops Revenue Estimates

10:40pm, Thursday, 24'th Feb 2022 Zacks Investment Research
Curis (CRIS) delivered earnings and revenue surprises of -15.38% and 3.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE